Funder: Foundation for Women's Cancer
Due Dates: October 7, 2026 (LOI) | December 9, 2026 (Full proposal) | February 9, 2027 (Award notification) | March 19–22, 2027 (Award presentation)
Funding Amounts: $50,000 for one year
Summary: Supports innovative research on therapeutic resistance and treatment response to improve personalized care for high-grade endometrial cancer.
Key Information: Research must take place at a U.S. institution; non-SGO applicants need an SGO co-investigator or sponsor.
Description
The Foundation for Women's Cancer (FWC) offers this grant through its 2026–2027 Endometrial/Uterine Cancer Grants program. It supports innovative research that advances treatment of high-grade endometrial cancer and addresses therapeutic resistance. Studies may investigate hormonal or endocrine resistance, immune escape, lineage plasticity, tumor-microenvironment interactions, the microbiome’s role in inflammation and treatment response, or biomarkers predicting responsiveness to current or emerging therapies.
Priority goes to projects combining cutting-edge technologies with translational approaches to identify actionable targets and accelerate therapeutic development. The goal is to improve the durability and personalization of care for patients with aggressive endometrial cancers. FWC’s broader research grants program prioritizes early career professionals and junior investigators.
